Dynastat

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
05-03-2024
Opinber matsskýrsla Opinber matsskýrsla (PAR)
13-07-2020

Virkt innihaldsefni:

parecoxib sodium

Fáanlegur frá:

Pfizer Europe MA EEIG

ATC númer:

M01AH04

INN (Alþjóðlegt nafn):

parecoxib

Meðferðarhópur:

Coxibs, Antiinflammatory and antirheumatic products

Lækningarsvæði:

Pain, Postoperative

Ábendingar:

For the short-term treatment of postoperative pain in adults.,

Vörulýsing:

Revision: 32

Leyfisstaða:

Authorised

Leyfisdagur:

2002-03-22

Upplýsingar fylgiseðill

                                52
B. PACKAGE LEAFLET
53
PACKAGE LEAFLET: INFORMATION FOR THE USER
DYNASTAT 40 MG POWDER FOR SOLUTION FOR INJECTION
parecoxib
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dynastat is and what it is used for
2.
What you need to know before you use Dynastat
3.
How to use Dynastat
4.
Possible side effects
5.
How to store Dynastat
6.
Contents of the pack and other information
1.
WHAT DYNASTAT IS AND WHAT IT IS USED FOR
Dynastat contains the active substance parecoxib.
Dynastat is used for the short-term treatment of pain in adults after
an operation. It is one of a family
of medicines called COX-2 inhibitors (this is short for
_cyclo-oxygenase-2 inhibitors_
). Pain and
swelling are sometimes caused by substances in the body called
_prostaglandins_
. Dynastat works by
lowering the amount of these prostaglandins.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE DYNASTAT
DO NOT USE DYNASTAT
-
if you are allergic to parecoxib or any of the other ingredients of
this medicine (listed in section 6)
-
if you have had a serious allergic reaction (especially a serious skin
reaction) to any medicines
-
if you have had an allergic reaction to a group of medicines called
“sulfonamides” (e.g. some
antibiotics used to treat infections)
-
if you currently have a gastric or intestinal ulcer or bleeding in the
stomach or gut
-
if you have had an allergic reaction to acetylsalicylic acid (aspirin)
or to other NSAIDs (e.g.
ibuprofen) or to COX-2 inhibitors. Reactions might include wheezing
(bronchospasm), badly
blocked nose, itchy skin, rash or swelling of the face, lips or
tongue, other allergic reactions or
nasal polyps after taking these medicines
-
if you are more than 6 months p
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dynastat 40 mg powder for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each vial contains 40 mg parecoxib (as 42.36 mg parecoxib sodium).
After reconstitution, the
concentration of parecoxib is 20 mg/ml. Each 2 ml of reconstituted
powder contains 40 mg of
parecoxib.
Excipient with known effect
This medicinal product contains less than 1 mmol sodium (23 mg) per
dose.
When reconstituted in sodium chloride 9 mg/ml (0.9%) solution,
Dynastat contains approximately
0.44 mmol of sodium per vial.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for injection (powder for injection).
White to off-white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the short-term treatment of postoperative pain in adults.
The decision to prescribe a selective cyclooxygenase-2 (COX-2)
inhibitor should be based on an
assessment of the individual patient's overall risks (see sections 4.3
and 4.4).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 40 mg administered intravenously (IV) or
intramuscularly (IM), followed
every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80
mg/day.
As the cardiovascular risk of COX-2 specific inhibitors may increase
with dose and duration of
exposure, the shortest duration possible and the lowest effective
daily dose should be used. There is
limited clinical experience with Dynastat treatment beyond three days
(see section 5.1).
Concomitant use with opioid analgesics
_ _
Opioid analgesics can be used concurrently with parecoxib, dosing as
described in the paragraph
above. In all clinical assessments parecoxib was administered at a
fixed time interval whereas the
opioids were administered on as needed basis.
Elderly
No dose adjustment is generally necessary in elderly patients (≥65
years). However, for elderly
patients weighing less than 50 kg, treatment should be initiated with
half the usual recommended dose
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 05-03-2024
Vara einkenni Vara einkenni búlgarska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla búlgarska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 05-03-2024
Vara einkenni Vara einkenni spænska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla spænska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 05-03-2024
Vara einkenni Vara einkenni tékkneska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla tékkneska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 05-03-2024
Vara einkenni Vara einkenni danska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla danska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 05-03-2024
Vara einkenni Vara einkenni þýska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla þýska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 05-03-2024
Vara einkenni Vara einkenni eistneska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla eistneska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 05-03-2024
Vara einkenni Vara einkenni gríska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla gríska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 05-03-2024
Vara einkenni Vara einkenni franska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla franska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 05-03-2024
Vara einkenni Vara einkenni ítalska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla ítalska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 05-03-2024
Vara einkenni Vara einkenni lettneska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla lettneska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 05-03-2024
Vara einkenni Vara einkenni litháíska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla litháíska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 05-03-2024
Vara einkenni Vara einkenni ungverska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla ungverska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 05-03-2024
Vara einkenni Vara einkenni maltneska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla maltneska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 05-03-2024
Vara einkenni Vara einkenni hollenska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla hollenska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 05-03-2024
Vara einkenni Vara einkenni pólska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla pólska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 05-03-2024
Vara einkenni Vara einkenni portúgalska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla portúgalska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 05-03-2024
Vara einkenni Vara einkenni rúmenska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla rúmenska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 05-03-2024
Vara einkenni Vara einkenni slóvakíska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 05-03-2024
Vara einkenni Vara einkenni slóvenska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla slóvenska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 05-03-2024
Vara einkenni Vara einkenni finnska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla finnska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 05-03-2024
Vara einkenni Vara einkenni sænska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla sænska 13-07-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 05-03-2024
Vara einkenni Vara einkenni norska 05-03-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 05-03-2024
Vara einkenni Vara einkenni íslenska 05-03-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 05-03-2024
Vara einkenni Vara einkenni króatíska 05-03-2024
Opinber matsskýrsla Opinber matsskýrsla króatíska 13-07-2020

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu